Antimicrobial susceptibility testing in biofilm-growing bacteria

Clinical Microbiology and Infection

Volumn 20, Issue 10, 2014, Pages 981-990

  Macia M D ^a   Rojo Molinero, E ^a   Oliver, A ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

Pseudomonas aeruginosa; Antibiotic; Antimicrobial resistance; Biofilm; Pharmacokinetic pharmacodynamic parameters; Susceptibility testing

Indexed keywords

RNA; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; BACTERIAL GROWTH; BACTERIAL INFECTION; BIOFILM; BIOFILM REACTOR; CALGARY BIOFILM DEVICE; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); FLOW CELL SYSTEM; GROWTH RATE; HORIZONTAL GENE TRANSFER; IN VITRO STUDY; MICROBIOLOGICAL PARAMETERS; MICROTITRE PLATE BASED ASSAY; MUTATIONAL ANALYSIS; NONHUMAN; NUTRIENT AVAILABILITY; PHARMACODYNAMICS; PLANKTON; PRIORITY JOURNAL; REVIEW; SUBSTRATUM SUSPENDING REACTOR; BIOLOGICAL MODEL; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; PROCEDURES; STANDARDS;

PSEUDOMONAS AERUGINOSA;

ANTI-INFECTIVE AGENTS; BIOFILMS; DRUG RESISTANCE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; PLANKTON;

EID: 84913621695     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12651     Document Type: Review

References (97)

1. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284: 1318-1322.
2. Stoodley P, Sauer K, Davies DG, Costerton JW. Biofilms as complex differentiated communities. Annu Rev Microbiol 2002; 56: 187-209.
3. Bjarnsholt T, Ciofu O, Molin S, Givskov M, Hoiby N. Applying insights from biofilm biology to drug development-can a new approach be developed? Nat Rev Drug Discov 2013; 12: 791-808.
4. O'Toole G, Kaplan HB, Kolter R. Biofilm formation as microbial development. Annu Rev Microbiol 2000; 54: 49-79.
5. Cucarella C, Solano C, Valle J, Amorena B, Lasa I, Penadés JR. Bap, a Staphylococcus aureus surface protein involved in biofilm formation. J Bacteriol 2001; 183: 2888-2896.
6. Branda SS, Vik S, Friedman L, Kolter R. Biofilms: the matrix revisited. Trends Microbiol 2005; 13: 20-26.
7. Costerton W, Veeh R, Shirtliff M, Pasmore M, Post C, Ehrlich G. The application of biofilm science to the study and control of chronic bacterial infections. J Clin Invest 2003; 112: 1466-1477.
8. Joo HS, Otto M. Molecular basis of in vivo biofilm formation by bacterial pathogens. Chem Biol 2012; 19: 1503-1513.
9. Costerton JW, Cheng KJ, Geesey GG et al. Bacterial biofilms in nature and disease. Annu Rev Microbiol 1987; 41: 435-464.
10. Costerton JW, Montanaro L, Arciola CR. Bacterial communications in implant infections: a target for an intelligence war. Int J Artif Organs 2007; 30: 757-763.
11. Wolcott RD, Rhoads DD, Bennet ME et al. Chronic wounds and the medical biofilm paradigm. J Wound Care 2010; 19: 45-46, 48-50, 52-53.
12. Bjarnsholt T, Jensen PO, Fiandaca MJ et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol 2009; 44: 547-558.
13. James GA, Swogger E, Wolcott RD et al. Biofilms in chronic wounds. Wound Repair Regen 2008; 16: 37-44.
14. Bjarnsholt T. The role of bacterial biofilms in chronic infections. APMIS Suppl 2013; 136: 1-51.
15. Gjodsbol K, Christensen JJ, Karlsmark T, Jorgensen B. Multiple bacterial species reside in chronic wounds: a longitudinal study. Int Wound J 2006; 3: 225-231.
16. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 2002; 15: 194-222.
17. Martinez-Solano L, Macia MD, Fajardo A, Oliver A, Martinez JL. Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease. Clin Infect Dis 2008; 47: 1526-1533.
18. Evans SA, Turner SM, Bosch BJ, Hardy CC, Woodhead MA. Lung function in bronchiestasis: the influence of Pseudomonas aeruginosa. Eur Respir J 1996; 9: 1601-1604.
19. Oliver A, Canton R, Campo P, Baquero F, Blázquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000; 288: 1251-1254.
20. Macia MD, Blanquer D, Togores B, Sauleda J, Pérez JL, Oliver A. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob Agents Chemother 2005; 49: 3382-3386.
21. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
22. Bonkat G, Rieken M, Siegel FP et al. Microbial ureteral stent colonization in renal transplant recipients: frequency and influence on the short-time functional outcome. Transpl Infect Dis 2011; 14: 57-63.
23. Flanders SA, Halm EA. Guidelines for community-acquired pneumonia: are they reflected in practice? Treat Respir Med 2004; 3: 67-77.
24. Hola V, Ruzicka F, Horka M. Microbial diversity in biofilm infections of the urinary tract with the use of sonication techniques. FEMS Immunol Med Microbiol 2010; 59: 525-528.
25. Paju S, Scannapieco FA. Oral biofilms, periodontitis, and pulmonary infections. Oral Dis 2007; 13: 508-512.
26. Stickler DJ. Bacterial biofilms in patients with indwelling urinary catheters. Nat Clin Pract Urol 2008; 5: 598-608.
27. Herrmann M, Vaudaux PE, Pittet D et al. Fibronectin, fibrinogen, and laminin act as mediators of adherence of clinical staphylococcal isolates to foreign material. J Infect Dis 1988; 158: 693-701.
28. Wimpenny J, Manz W, Szewzyk U. Heterogeneity in biofilms. FEMS Microbiol Rev 2000; 24: 661-671.
29. Bjarnsholt T, Jensen PO, Burmolle M et al. Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent. Microbiology 2005; 151: 373-383.
30. Alhede M, Kragh KN, Qvortrup K et al. Phenotypes of non-attached Pseudomonas aeruginosa aggregates resemble surface attached biofilm. PLoS ONE 2011; 6: e27943.
31. Mah TF, O'Toole GA. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 2001; 9: 34-39.
32. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002; 15: 167-193.
33. Lewis K. Multidrug tolerance of biofilms and persister cells. Curr Top Microbiol Immunol 2008; 322: 107-131.
34. Alipour M, Suntres ZE, Omri A. Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa. J Antimicrob Chemother 2009; 64: 317-325.
35. De Beer D, Srinivasan R, Stewart PS. Direct measurement of chlorine penetration into biofilms during disinfection. Appl Environ Microbiol 1994; 60: 4339-4344.
36. Costerton JW, Montanaro L, Arciola CR. Biofilm in implant infections: its production and regulation. Int J Artif Organs 2005; 28: 1062-1068.
37. Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappin-Scott HM. Microbial biofilms. Annu Rev Microbiol 1995; 49: 711-745.
38. Hoiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents 2010; 35: 322-332.
39. Werner E, Roe F, Bugnicourt A et al. Stratified growth in Pseudomonas aeruginosa biofilms. Appl Environ Microbiol 2004; 70: 6188-6196.
40. Borriello G, Werner E, Roe F, Kim AM, Ehrlich GD, Stewart PS. Oxygen limitation contributes to antibiotic tolerance of Pseudomonas aeruginosa in biofilms. Antimicrob Agents Chemother 2004; 48: 2659-2664.
41. Yoon SS, Coakley R, Lau GW et al. Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions. J Clin Invest 2006; 116: 436-446.
42. Lewis K. Riddle of biofilm resistance. Antimicrob Agents Chemother 2001; 45: 999-1007.
43. Lewis K. Persister cells. Annu Rev Microbiol 2010; 64: 357-372.
44. Whiteley M, Bangera MG, Bumgarner RE et al. Gene expression in Pseudomonas aeruginosa biofilms. Nature 2001; 413: 860-864.
45. Mulet X, Moya B, Juan C et al. Antagonistic interactions of Pseudomonas aeruginosa antibiotic resistance mechanisms in planktonic but not biofilm growth. Antimicrob Agents Chemother 2011; 55: 4560-4568.
46. Macia MD, Perez JL, Molin S, Oliver A. Dynamics of mutator and antibiotic-resistant populations in a pharmacokinetic/pharmacodynamic model of Pseudomonas aeruginosa biofilm treatment. Antimicrob Agents Chemother 2011; 55: 5230-5237.
47. Mao EF, Lane L, Lee J, Miller JH. Proliferation of mutators in a cell population. J Bacteriol 1997; 179: 417-422.
48. Lujan AM, Macia MD, Yang L, Molin S, Oliver A, Smania AM. Evolution and adaptation in Pseudomonas aeruginosa biofilms driven by mismatch repair system-deficient mutators. PLoS ONE 2011; 6: e27842.
49. Conibear TC, Collins SL, Webb JS. Role of mutation in Pseudomonas aeruginosa biofilm development. PLoS ONE 2009; 4: e6289.
50. Boles BR, Singh PK. Endogenous oxidative stress produces diversity and adaptability in biofilm communities. Proc Natl Acad Sci USA 2008; 105: 12503-12508.
51. Driffield K, Miller K, Bostock JM, O'Neill AJ, Chopra I. Increased mutability of Pseudomonas aeruginosa in biofilms. J Antimicrob Chemother 2008; 61: 1053-1056.
52. Bagge N, Hentzer M, Andersen JB, Ciofu O, Givskov M, Høiby N. Dynamics and spatial distribution of beta-lactamase expression in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2004; 48: 1168-1174.
53. McBain AJ. Chapter 4: in vitro biofilm models: an overview. Adv Appl Microbiol 2009; 69: 99-132.
54. Lourenço A, Coenye T, Goeres D et al. Minimum information about a biofilm experiment (MIABiE): standards for reporting experiments and data on sessile microbial communities living at interfaces. Pathog Dis 2014; 70: 250-256.
55. Christensen GD, Simpson WA, Younger JJ et al. Adherence of coagulase-negative staphylococci to plastic tissue culture plates: a quantitative model for the adherence of staphylococci to medical devices. J Clin Microbiol 1985; 22: 996-1006.
56. Peeters E, Nelis HJ, Coenye T. Comparison of multiple methods for quantification of microbial biofilms grown in microtiter plates. J Microbiol Methods 2008; 72: 157-165.
57. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 1999; 37: 1771-1776.
58. Mulet X, Macia MD, Mena A, Juan C, Pérez JL, Oliver A. Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. Antimicrob Agents Chemother 2009; 53: 1552-1560.
59. Klausen M, Heydorn A, Ragas P et al. Biofilm formation by Pseudomonas aeruginosa wild type, flagella and type IV pili mutants. Mol Microbiol 2003; 48: 1511-1524.
60. Palmer RJ Jr. Microscopy flowcells: perfusion chambers for real-time study of biofilms. Methods Enzymol 1999; 310: 160-166.
61. Weiss NM, Sternberg C, Molin S, Regenberg B. Pseudomonas aeruginosa and Saccharomyces cerevisiae biofilm in flow cells. J Vis Exp 2011; 15: pii: 238.
62. Doring G, Flume P, Heijerman H, Elborn JS. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 2012; 11: 461-479.
63. O'Toole GA, Kolter R. Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development. Mol Microbiol 1998; 30: 295-304.
64. Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 2004; 42: 1915-1922.
65. Christersen BB, Sternberg G, Andersen JB et al. Molecular tools for study of biofilm physiology. Methods Enzymol 1999; 310: 20-42.
66. Spoering AL, Lewis K. Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials. J Bacteriol 2001; 183: 6746-6751.
67. Harrison JJ, Ceri H, Yerly J et al. The use of microscopy and three-dimensional visualization to evaluate the structure of microbial biofilms cultivated in the Calgary Biofilm Device. Biol Proced Online 2006; 8: 194-215.
68. Fjeld C, Schuller RB. Biofilm formation during hexadecane degradation and the effects of flow field and shear stress. Annu Trans Nordic Rheol Soc 2013: 21: 341-343.
69. Amorena B, Gracia E, Monzón M et al. Antibiotic susceptibility assay for Staphylococcus aureus in biofilms developed in vitro. J Antimicrob Chemother 1999; 44: 43-55.
70. Ramage G, Vandewalle K, Wickes BL, López-Ribot JL. Characteristics of biofilm formation by Candida albicans. Rev Iberoam Micol 2001; 18: 163-170.
71. Müsken M, Di Fiore S, Römling U, Häussler S. A 96-well-plate-based optical method for the quantitative and qualitative evaluation of Pseudomonas aeruginosa biofilm formation and its application to susceptibility testing. Nat Protoc 2010; 5: 1460-1469.
72. Vandevelde NM, Van Bambeke F. Antibiotic activity against naive and induced Streptococcus pneumoniae biofilms in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2014; 58: 1348-1358.
73. Djordjevic D, Wiedmann M, McLandsborough LA. Microtiter plate assay for assessment of Listeria monocytogenes biofilm formation. Appl Environ Microbiol 2002; 68: 2950-2958.
74. Olson ME, Ceri H, Morck DW, Buret AG. Biofilm bacteria: formation and comparative susceptibility to antibiotics. Can J Vet Res 2002; 66: 86-92.
75. Bardouniotis E, Huddleston W, Ceri H, Olson ME. Characterization of biofilm growth and biocide susceptibility testing of Mycobacterium phlei using the MBEC assay system. FEMS Microbiol Lett 2001; 203: 263-267.
76. Parahitiyawa NB, Samaranayake YH, Samaranayake LP et al. Interspecies variation in Candida biofilm formation studied using the Calgary biofilm device. APMIS 2006; 114: 298-306.
77. Tomlin KL, Malott RJ, Ramage G, Storey DG, Sokol PA, Ceri H. Quorum-sensing mutations affect attachment and stability of Burholderia cenocepacia biofilms. Appl Environ Microbiol 2005; 71: 5208-5218.
78. Moormeler DE, Bayles KW. Examination of Staphylococcus epidermidis biofilms using flow-cell technology. Methods Mol Biol 2014; 1106: 143-155.
79. Honraet K, Goetghebeur E, Nelis HJ. Comparison of three assays for the quantification of Candida biomass in suspension and CDC reactor grown biofilms. J Microbiol Methods 2005; 63: 287-295.
80. Williams DL, Bloebaum RD. Observing the biofilm matrix of Staphylococcus epidermidis ATCC 35984 grown using the CDC biofilm reactor. Microsc Microanal 2010; 16: 143-152.
81. Parra-Ruiz J, Bravo-Molina A, Peña-Monje A, Hernández-Quero J. Activity of linezolid and high-dose daptomycin, alone or in combination, in an in vitro model of Staphylococcus aureus biofilm. J Antimicrob Chemother 2012; 67: 2682-2685.
82. Tote K, Vanden Berghe D, Maes L, Cos P. A new colorimetric microtitre model for the detection of Staphylococcus aureus biofilms. Lett Appl Microbiol 2008; 46: 249-254.
83. Tote K, Horemans T, Vanden BD, Maes L, Cos P. Inhibitory effect of biocides on the viable masses and matrices of Staphylococcus aureus and Pseudomonas aeruginosa biofilms. Appl Environ Microbiol 2010; 76: 3135-3142.
84. Pawley J. Handbook of biological confocal microscopy. In: Pawley JB, ed. 3rd edn. Madison, WI: Zoology Department. University of Wisconsin-Madison, 2006.
85. Haagensen JA, Klausen M, Ernst RK et al. Differentiation and distribution of colistin- and sodium dodecyl sulfate-tolerant cells in Pseudomonas aeruginosa biofilms. J Bacteriol 2007; 189: 28-37.
86. Heydorn A, Nielsen AT, Hentzer M et al. Quantification of biofilm structures by the novel computer program COMSTAT. Microbiology 2000; 146: 2395-2407.
87. Kim J, Pitts B, Stewart PS, Camper A, Yoon J. Comparison of the antimicrobial effects of chlorine, silver ion, and tobramycin on biofilm. Antimicrob Agents Chemother 2008; 52: 1446-1453.
88. Riera E, Macia MD, Mena A et al. Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1. J Antimicrob Chemother 2010; 65: 1399-1404.
89. Fernandez-Olmos A, Garcia-Castillo M, Maiz L, Lamas A, Baquero F, Cantón R. In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients. Int J Antimicrob Agents 2012; 40: 173-176.
90. Hengzhuang W, Wu H, Ciofu O, Song Z, Høiby N. Pharmacokinetics/pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2011; 55: 4469-4474.
91. Hengzhuang W, Wu H, Ciofu O, Song Z, Hoiby N. In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection. Antimicrob Agents Chemother 2012; 56: 2683-2690.
92. Hengzhuang W, Hoiby N, Ciofu O. Pharmacokinetics and pharmacodynamics of antibiotics in biofilm infections of Pseudomonas aeruginosa in vitro and in vivo. Methods Mol Biol 2014; 1147: 239-254.
93. Hengzhuang W, Ciofu O, Yang L et al. High β-lactamase levels change the pharmacodynamics of β-lactam antibiotics in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2013; 57: 196-204.
94. Pamp SJ, Gjermansen M, Johansen HK, Tolker-Nielsen T. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes. Mol Microbiol 2008; 68: 223-240.
95. Moskowitz SM, Emerson JC, McNamara S, Shell RD. Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection. Pediatr Pulmonol 2011; 46: 184-192.
96. Waters V, Ratjen F. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Cochrane Database Syst Rev 2012; 1: CD009528.
97. Kirchner S, Fothergill JL, Wright EA, James CE, Mowat E, Winstanley C. Use of artificial sputum medium to test antibiotic efficacy against Pseudomonas aeruginosa in conditions more relevant to the cystic fibrosis lung. J Vis Exp 2012; e3857.